Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tyrosine kinase inhibitors and interferon‐α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines

The FASEB Journal(2020)10.1096/fj.201802061rrSource: DataRank Database

Tyrosine kinase inhibitors and interferon‐α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines is a research paper published in The FASEB Journal (2020). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.38)OA: hybridTopics (48)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Vibeke Andresen ORCID,Stein‐Erik Gullaksen ORCID,Pilar Ayuda‐Durán ORCID,Mihaela Popa ORCID,Randi Hovland ORCID

Live enrichment

PubMed:31945226 OpenAlex:https://openalex.org/W2998946380

Kreftforeningen

Grant: 205729

Kreftforeningen

Grant: 182524

Norges Forskningsråd

Grant: 223250

Norges Forskningsråd

Grant: 262652

Norges Forskningsråd

Grant: 294916

NCI NIH HHS

Grant: HHSN261200800001E

FWCI

1.38

Citation Percentile

0.8%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://faseb.onlinelibrary.wiley.com/doi/pdfdirect/10.1096/fj.201802061RR

publisherhttps://faseb.onlinelibrary.wiley.com/doi/pdfdirect/10.1096/fj.201802061RR

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1096%2Ffj.201802061RR

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201802061RR

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1096/fj.201802061RR

Fields of Study

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchHER2/EGFR in Cancer ResearchAnimalsCell AdhesionCell CommunicationCell Line, TumorCells, CulturedFemaleFluorescent Antibody TechniqueHumansImmunoblottingIntegrin beta1Interferon-alphaK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiceMicroscopy, Electron, ScanningProtein Kinase InhibitorsXenograft Model Antitumor Assays

MeSH Terms

AnimalsCell AdhesionCell CommunicationCells, CulturedFemaleFluorescent Antibody TechniqueHumansMicroscopy, Electron, ScanningImmunoblottingLeukemia, Myelogenous, Chronic, BCR-ABL PositiveInterferon-alphaIntegrin beta1K562 CellsXenograft Model Antitumor AssaysCell Line, TumorProtein Kinase InhibitorsMice

Keywords

MedicineUniversity hospitalCancerFamily medicineOncologyInternal medicinecell adhesionchronic myeloid leukemiainterferon-αtunneling nanotubestyrosine kinase inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being